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BACKGROUND: A multi-institutional nomogram for predicting disease-free survival (DFS) and overall survival (OS) in patients with
primary retroperitoneal sarcoma (RPS) incorporating relevant prognostic factors not included in the American Joint Committee on
Cancer staging system for soft tissue sarcoma has been reported. The authors validated this nomogram with an independent, transat-
lantic cohort. METHODS: Data from patients with RPS who were undergoing definitive resection at 1 of 6 sarcoma centers in Europe
and North America (“validation set”) were used to validate a RPS nomogram developed from 3 other centers (“development set”).
The nomogram incorporated 6 variables: age, tumor size, grade, histologic subtype, multifocality, and quality of surgery. Nomogram-
predicted probabilities were stratified into 6 subgroups and compared with observed outcomes. Discriminative ability was quantified
by Harrell C statistics. RESULTS: The validation and development sets included 631 and 523 patients, respectively, all of whom under-
went surgical resection at the institutions represented. The 7-year DFS and OS rates for the validation set were 38% (95% confidence
interval, 34%-43%) and 58% (95% confidence interval, 53%-63%), respectively. All 6 nomogram variables were found to be independ-
ently prognostic. The corrected Harrell C statistics concordance index values for the validation set were 0.69 for DFS and 0.73 for
OS, which were similar to those for the development set, suggesting good calibration of the nomogram in the validation cohort. CON-
CLUSIONS: The RPS nomogram was externally validated using a larger, independent cohort. The nomogram can be generalized to
patients undergoing surgery for RPS by specialized sarcoma surgeons at sarcoma centers. The nomogram provides a more individual-
ized and disease-relevant estimation of OS compared with the American Joint Committee on Cancer classification. Cancer
2016;122:1417-24. VC 2016 American Cancer Society.
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INTRODUCTION
Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS).1 Unique characteristics of
RPS make traditional staging using the 7th edition of the American Joint Committee on Cancer (AJCC) system a challenge.
Histologic subtype, multifocality, and site of origin are proven risk factors that are prognostic of outcome in patients with
STS, but are not included in the AJCC TNM staging for STS or stage grouping.2-5 Furthermore, the unique locoregional
and distant patterns of disease recurrence for specific RPS histologies are not reflected in the stage-based outcomes. Finally,
the majority of RPS measure 15 to 20 cm in size, and only approximately 6% of RPS reported in the Surveillance, Epidemi-
ology, and End Results program measure <5 cm in size (the key discriminatory size used in AJCC STS staging).6,7 This,
Corresponding author: Chandrajit P. Raut, MD, MSc, Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital, 75 Francis St, Bos-
ton, MA 02115; Fax: (617) 394-3052; craut@bwh.harvard.edu
1Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; 2Center for Sarcoma and
Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 3Department of Medical Statistics, Biometry and Bioinformatics,
IRCCS Foundation National Cancer Institute, Milan, Italy; 4Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom;
5Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, Ontario, Canada; 6Department of Surgery, University of
Toronto, Toronto, Ontario, Canada; 7Division of Surgical Oncology and Thoracic Surgery, Mannheim University Hospital, Mannheim, Germany; 8Department of Sur-
gical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 9Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 10Department of Surgery, IRCCS Foundation National Cancer Institute, Milan, Italy; 11Depart-
ment of Cancer Medicine, IRCCS Foundation National Cancer Institute, Milan, Italy; 12Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam,
The Netherlands; 13Department of Surgery, Gustave Roussy Institute, Villejuif, France; 14Division of Surgical Oncology, Department of Surgery, Ohio State Univer-
sity Medical Center, Columbus, Ohio; 15Department of Surgery, Curie Institute, Paris, France
Presented at the 18th European Cancer Congress (ECCO)-40th European Society for Medical Oncology (ESMO) European Cancer Congress; September 25-29,
2015; Vienna, Austria.
DOI: 10.1002/cncr.29931, Received: December 15, 2015; Accepted: January 7, 2016, Published online February 24, 2016 in Wiley Online Library
(wileyonlinelibrary.com)
Cancer May 1, 2016 1417
Original Article
coupled with the finding that all RPS are by definition
“deep,” means that approximately 94% of RPS are by defi-
nition T2b tumors, and therefore tumor grade is the only
variable that discriminates the majority of RPS into the dis-
crete stages of IIB and III.
Nomograms provide a more disease-specific and clin-
ically relevant prognostic model for predicting various out-
comes, including overall survival (OS), disease-free survival
(DFS), and local recurrence-free survival rates within a spe-
cific time frame compared with the AJCC system, particu-
larly for STS. An initial STS nomogram from the
Memorial Sloan Kettering Cancer Center (MSKCC)
incorporated a variety of histologies and sites of origin.5
Although RPS were included, RPS/intra-abdominal sarco-
mas accounted for only 13% of the original development
cohort. The limited usefulness of the AJCC STS staging
system for RPS was a critical impetus to the eventual devel-
opment of the initial single-institution, RPS-specific
nomograms from high-volume sarcoma centers.2,4 These
were critical in the evolution of expert opinion that has sup-
ported the use of such nomograms. However, a shortcom-
ing of most single-institution nomograms is that they may
reflect the treatment biases of experienced sarcoma centers
and thus may not bemore broadly applicable.
The first multi-institutional RPS nomogram (to the
best of our knowledge) was developed from patients under-
going surgical resection of primary RPS between 1999 and
2009 at the sarcoma centers at the National Cancer Insti-
tute inMilan, Italy; The University of TexasMDAnderson
Cancer Center in Houston, Texas; and the University of
California at Los Angeles and was externally validated using
another data set from 2001 to 2010 from the Gustave
Roussy Institute (Villejuif, France).8 Unlike prior nomo-
grams, this one included size and age as continuous rather
than categorical variables, as well as relevant RPS histolo-
gies, tumor grade, multifocality, and completeness of surgi-
cal resection. The 7-year DFS and OS rates could be
predicted with accuracy (Fig. 1 A and B). This provided a
more broadly applicable nomogram.
This multi-institution RPS nomogram is currently
under consideration for inclusion in the forthcoming 8th
edition of the AJCC staging system. To determine
whether adoption of this nomogram by the AJCC is justi-
fied, we decided to critically evaluate the nomogram by
externally validating it with a larger data set collected from
other high-volume sarcoma centers.
MATERIALS AND METHODS
Data regarding patients with primary RPS undergoing
surgery with curative intent at 6 dedicated sarcoma centers
in 6 countries from January 2002 through December
2011 were collected (“validation set”). Patients who had
undergone macroscopically incomplete initial surgical
resection of RPS at an outside referring institution were
excluded. Patients with retroperitoneal presentations of
gastrointestinal stromal tumor, desmoplastic small round
cell tumor, extraosseous Ewing sarcoma/primitive neuro-
ectodermal tumor, uterine sarcoma histologic subtypes,
alveolar/embryonal rhabdomyosarcoma, and desmoid
fibromatosis were excluded.
Histologic subtypes incorporated within the multi-
institutional RPS nomogram included well-differentiated
liposarcoma, dedifferentiated liposarcoma, leiomyosarcoma,
unclassified/undifferentiated pleomorphic sarcoma, malig-
nant peripheral nerve sheath tumor, solitary fibrous tumor,
and other. Liposarcomas were classified as “well differ-
entiated” if only a well-differentiated component and no
dedifferentiated component was present and as
“dedifferentiated” if such a component was present regard-
less of tumor extent. All tumors were graded using the Feder-
ation Nationale des Centres de Lutte Contre le Cancer
(FNCLCC) (National Federation of Centers for the Fight
Against Cancer) grading system.9 The one treatment vari-
able that was included in the nomogram was extent of surgi-
cal resection, with macroscopically complete (R0, negative
microscopic margin; R1, positive microscopicmargin) surgi-
cal resections classified as “complete” and macroscopically
incomplete (R2) surgical resections classified as
“incomplete.” Patients were followed prospectively with
clinical examination and routine imaging (usually computed
tomography scans of the chest, abdomen, and pelvis) every 3
months to 4 months for the first 2 years, every 6 months for
the following 3 years, and yearly thereafter. Local and distant
disease recurrence and death were recorded as events.
The multi-institutional RPS nomogram incorpo-
rated 6 clinical characteristics and treatment variables to
predict DFS and OS: age (in years) at the time of diagno-
sis as a continuous variable (OS only), tumor size (in cen-
timeters) as a continuous variable, FNCLCC grade (1, 2,
or 3), histologic subtype (well-differentiated liposarcoma,
dedifferentiated liposarcoma, leiomyosarcoma, unclassi-
fied/undifferentiated pleomorphic sarcoma, malignant
peripheral nerve sheath tumor, solitary fibrous tumor,
and other), multifocality at the time of initial presentation
(yes/no), and extent of surgical resection (complete,
incomplete [for OS only]).8
Statistical Analysis
Cohort characteristics, treatment variables, and outcomes
of the validation set were compared with the original
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Figure 1. Nomogram for 7-year (A) disease-free survival (DFS) and (B) overall survival (OS) in patients with primary retroperito-
neal sarcoma. FNCLCC indicates Federation Nationale des Centres de Lutte Contre le Cancer (National Federation of Centers for
the Fight Against Cancer); Lipo DD, dedifferentiated liposarcoma; Lipo WD, well-differentiated liposarcoma; LMS, leiomyosar-
coma; MPNST, malignant peripheral nerve sheath tumor; SFT, solitary fibrous tumor; UPS, unclassified/undifferentiated pleomor-
phic sarcoma. Reprinted from Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft
tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets.
J Clin Oncol. 2013;31:1649-1655 with permission from American Society of Clinical Oncology.8
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“development set” from which the nomogram was con-
structed using the Mann-Whitney-Wilcoxon test or the
chi-square test when continuous or categorical variables,
respectively, were involved in the comparison.
OS and DFS curves were estimated using the
Kaplan-Meier method. OS was computed as the interval
between the date of surgery and the date of death from
any cause. DFS was computed as the interval between the
date of surgery and the date of first disease recurrence
(regardless of whether it was local, distant, or both) or
death from any cause, whichever occurred first.
External validation was performed by applying the
nomogram to the patients in the validation set. Calibra-
tion plots were used to compare nomogram-predicted
probabilities with observed outcomes; in a perfectly cali-
brated nomogram, the observed and predicted outcomes
would align along the 458 line of the calibration plot. The
discriminative ability of the nomogram was quantified by
the Harrell C statistics.
The statistical analyses did not include patients with
missing values among the nomogram variables and were
conducted using SAS statistical software (SAS Institute
Inc, Cary, NC) and R statistical software (R Foundation,
Vienna, Austria; http://www.r-project.org/)
RESULTS
The validation set included 631 patients who underwent
surgical resection with curative intent for primary RPS at 1
of 6 sarcoma centers: 1) Mount Sinai Hospital/Princess
Margaret Cancer Centre at the University of Toronto (To-
ronto, Ontario, Canada); 2) Brigham andWomen’s Hospi-
tal, Dana-Farber Cancer Institute, Harvard Medical School
(Boston, Mass); 3) Royal Marsden Hospital NHS Founda-
tion Trust (London, UK); 4) Mannheim University Hospi-
tal (Mannheim, Germany); 5) Netherlands Cancer Institute
(Amsterdam, the Netherlands); and 6) Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology
(Warsaw, Poland). Cohort variables for the original devel-
opment set and validation set are compared in Table 1. The
validation set was characterized by a larger median tumor
size (21 cm vs 16 cm; P<.0001), more patients with grade 2
tumors (40% vs 23%), and fewer patients with grade 3
tumors (27% vs 49%) (overall P<.0001). Treatment details
are summarized in Table 2. Completeness of surgical resec-
tion and use of radiotherapy were similar between the 2
cohorts, but the validation set included fewer patients
treated with chemotherapy (9% vs 40%; P<.0001).
Outcomes are summarized in Table 3. The median
follow-up in the validation set was 58 months (interquar-
tile range, 36-87 months). Rates of local disease recur-
rence, distant disease recurrence, death, and death
without disease recurrence were similar in the validation
and development cohorts. Figure 2 shows the DFS and
OS curves for both the development and validation sets.
In the validation set, the 7-year DFS rate was 38.4%
(95% confidence interval [95% CI], 33.9%-43.4%) and
the 7-year OS rate was 58.0% (95% CI, 53.1%-63.4%);
the corresponding estimates in the development set were
35.7% (95% CI, 30.3%-42.1%) and 50.5% (95% CI,
44.4%-57.4%), respectively.
TABLE 1. Demographic, Clinical, and Histologic Characteristics of Patients in the Retroperitoneal Sarcoma
Nomogram Development and Validation Sets
Variable
Development Set
N 5 523 (%)
Validation Set
N 5 631 (%) P
Median age, y 57 (IQR, 48–67; range, 16–88) 59 (IQR, 49–68; range, 18–95) .248
Median tumor size, cm 16 (IQR, 10–26; range, 2–75) 21 (IQR, 13–30; range, 1–65) <.0001
FNCLCC grade 1 147 (28.1) 193 (32.7) <.0001
2 122 (23.3) 235 (39.8)
3 254 (48.6) 162 (27.5)
Missing data 0 41
Histologic subtype LMS 92 (17.8) 137 (21.7) <.0001
DDLPS 155 (30.0) 231 (36.6)
WDLPS 121 (23.4) 158 (25.0)
MPNST 16 (3.1) 17 (2.7)
UPS 70 (13.5) 18 (2.9)
SFT 26 (5.0) 33 (5.2)
Other 37 (7.2) 37 (5.9)
Missing data 6 0
Multifocality No 490 (93.7) 565 (89.5) 0.016
Yes 33 (6.3) 66 (10.5)
Abbreviations: DDLPS, dedifferentiated liposarcoma; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer (National Federation of Centers for
the Fight Against Cancer); IQR, interquartile range; LMS, leiomyosarcoma; MPNST, malignant peripheral nerve sheath tumor; SFT, solitary fibrous tumor; UPS,
unclassified/undifferentiated pleomorphic sarcoma; WDLPS, well-differentiated liposarcoma.
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In the validation set, the Harrell C statistic concord-
ance index values were very similar to those obtained in
the development set for both DFS and OS (DFS: 0.69 vs
0.71 [Fig. 3 A]; OS: 0.73 vs 0.74 [Fig. 3 B]).
DISCUSSION
Correlation between observed and nomogram-predicted
DFS and OS rates suggests good calibration of the multi-
institutional RPS nomogram in a larger, independent vali-
dation cohort.8 The data presented here demonstrate that
the nomogram applies well to patients undergoing surgery
for primary RPS performed by specialized sarcoma sur-
geons at sarcoma centers. Because the data are based on
outcomes after surgical resection of primary RPS, this
nomogram is not applicable to patients who have under-
gone surgical resection for recurrent disease, unlike the
single-institution nomogram from The University of
Texas MD Anderson Cancer Center.4 Furthermore,
unlike the recently reported RPS nomogram from
MSKCC, the multi-institutional RPS nomogram vali-
dated in the current study does not incorporate vascular
resection or association with a prior radiation field as in-
dependent variables because these were very rare in the de-
velopment set.3 In addition, this international, multi-
institution RPS nomogram includes age and tumor size as
continuous rather than categorical variables; the latter is
true of some of the single-institution nomograms.3,4
Although the relevance or advantage of such detail may be
debated, we have found that some of the largest tumors
(>30 cm) may have a better prognosis than those meas-
uring in the range of 20 to 30 cm, reflecting a more favor-
able tumor biology in tumors that have reached such a
large size likely through prolonged indolent growth.
As a nomogram constructed based on data from mul-
tiple institutions and validated by other additional institu-
tions, this nomogram has broad applicability. Nevertheless,
it reflects predicted outcomes in patients undergoing such
procedures by experienced sarcoma surgeons and multidis-
ciplinary teams at high-volume sarcoma centers. Data used
as part of the initial development set and the current valida-
tion set were pooled in a previously reported survival analy-
sis.6 OS outcomes from that combined data set were
favorable when compared with OS reported in a Surveil-
lance, Epidemiology, and End Results analysis, which
included surgical resections performed in a percentage of
regions in the United States, bearing in mind all the caveats
of such a post hoc comparison. Nevertheless, the nomo-
gram in the current study establishes a benchmark against
which other institutional outcomes may be compared.
The multi-institutional RPS nomogram in the cur-
rent study provides a more individualized and disease-
relevant estimation of OS than the AJCC classification.
The 7th edition of the AJCC classification essentially only
risk stratifies RPS based on grade alone (which still
remains the most important prognosticator) because
approximately 95% of RPS are T2b tumors. The current
multi-institutional RPS nomogram provides a more spe-
cific estimation of both DFS and OS and, based on the
corroboration of the external validation set reported
TABLE 2. Treatments for Patients in the Development and Validation Sets
Variable
Development Set
N 5 523 (%)
Validation Set
N 5 631 (%) P
Extent of resection Complete (R0/R1) 475 (90.8) 598 (94.8) .013
Incomplete (R2) 48 (9.2) 33 (5.2)
Chemotherapy Yes 207 (39.6) 57 (9.0) <.0001
No 316 (60.4) 574 (91.0)
Radiotherapy Yes 193 (36.9) 200 (31.7) .073
No 330 (63.1) 431 (68.3)
Abbreviations: R0 resection, macroscopically complete surgical resection with negative microscopic margins; R1 resection, macroscopically complete surgical
resection with positive microscopic margins; R2, macroscopically incomplete surgical resection.
TABLE 3. Patient Outcomes in the Development
and Validation Sets
Development
Set
N 5 523 (%)
Validation
Set
N 5 631 (%) P
Median follow-up,
mo
45
(IQR, 22–72)
58
(IQR, 36–87)
<.001a
Recurrences Local 130 (24.9) 161 (25.5) .092b
Distant 94 (18.0) 117 (18.5) .377b
Deaths 171 (32.7) 205 (32.5) .009c
Deaths without
recurrence
34 (6.5) 52 (8.2) .568b
Abbreviation: IQR, interquartile range.
aP value at log-rank test for the comparison of the “reverse Kaplan-Meier”
curves.
bP value at Gray test for the comparison between the crude cumulative
incidence curves of local recurrence, distant metastasis, and deaths with-
out recurrence.
cP value at log-rank test for the comparison of the Kaplan-Meier curves.
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herein, will be proposed for inclusion in the 8th edition of
the AJCC classification.
Nomograms have the flexibility to incorporate addi-
tional independent prognostic factors. The use of chemo-
therapy did not appear to impact outcome in the
nomogram used herein. There was a significantly lower
percentage of patients undergoing chemotherapy in the
validation set compared with the development set (9% vs
40%; P<.0001) (Table 2), reflecting institutional bias in
default therapy for RPS. However, this did not appear to
affect the predictive value of the multi-institutional RPS
nomogram. The percentage of patients undergoing radio-
therapy was similar in the 2 data sets. The ongoing phase
3 randomized study of preoperative radiotherapy plus sur-
gery versus surgery alone for patients with retroperitoneal
sarcoma (STRASS) trial will define the standard of care
with respect to the potential benefit of preoperative radio-
therapy for RPS. If found to be independently predictive
Figure 2. Kaplan-Meier curves for (A) disease-free survival and (B) overall survival for the development (black) and validation
(red) sets.
Figure 3. Calibration plot for external validation of the (A) disease-free survival (DFS) and (B) overall survival (OS) nomograms.
Nomogram-predicted probabilities were stratified into 6 equally sized subgroups. For each subgroup, the mean predicted proba-
bility (x-axis) was plotted against the Kaplan-Meier probability observed in the validation cohort (y-axis). Vertical lines indicate
the 95% confidence intervals of the Kaplan-Meier estimates. The dashed line in each panel indicates the reference line along
which an ideal nomogram would lie.
Original Article
1422 Cancer May 1, 2016
of outcome, preoperative radiotherapy could be added as
a separate prognostic factor in the future.
There has been much debate recently concerning the
optimal extent of surgical resection.10-15 In the recent
single-institution nomogram reported by Tan et al, the
number of organs resected was incorporated.3 However,
in the multi-institutional RPS nomogram validated in the
current study, organ resection was not included because
we noted institutional variation in the number of organs
resected. This may well reflect not only different institu-
tional practices, but also the broad variability of presenta-
tion of these tumors, which may be represented
differently in the various institutional case mixes. In the
series reporting combined outcomes from the majority of
the institutions in the development and validation sets,
the number of organs resected was not found to be an in-
dependent prognosticator.6 Thus, the number of organs
resected is not as predictive of the extent of surgical resec-
tion as in single-institution nomograms, which reflect a
more uniform treatment strategy.3 The number of organs
resected remains a prognosticator only as long as it reflects
a uniform approach to the removal of the disease, which
then still has to be tailored to the single patient.
Eventually, the DFS nomogram could be replaced
with separate nomograms for local and distant recurrence-
free survival. Whether OS or disease-specific survival is a
more optimal measure of long-term outcome is a matter
of debate. A small percentage of patients in each of the de-
velopment and validation cohorts died without develop-
ing disease recurrence (7% and 8%, respectively). Future
editions may include a disease-specific survival nomo-
gram, as the recent study fromMSKCC study reported.3
Conclusions
External validation of the multi-institutional RPS nomo-
gram established its broad applicability in predicting out-
comes in patients with primary RPS who were treated at
experienced centers, and supports its inclusion in the 8th
edition of the AJCC classification.
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